UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 12, 2007
ADVANCED LIFE SCIENCES HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
Delaware |
| 000-51436 |
| 30-0296543 |
(State or other jurisdiction |
| (Commission |
| (I.R.S. Employer |
of incorporation) |
| File Number) |
| Identification No.) |
|
|
|
|
|
|
| 1440 Davey Road |
|
|
|
| Woodridge, Illinois |
| 60517 |
|
| (Address of principal executive offices) |
| (Zip Code) |
(630) 739-6744
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On September 12, 2007, Advanced Life Sciences Holdings, Inc. (the “Company”) filed an application to transfer the listing of the Company’s common stock from the NASDAQ Global Market to the NASDAQ Capital Market. The Company would maintain its “ADLS” trading symbol on NASDAQ and the Company does not expect any interruption in the trading of its common stock. The Company currently complies with the continued listing requirements of the NASDAQ Capital Market. If the Company’s application for listing on the NASDAQ Capital Market is approved, the Company will no longer be subject to the continued listing requirements of the NASDAQ Global Market and will instead be subject to the continued listing requirements of the NASDAQ Capital Market.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ADVANCED LIFE SCIENCES HOLDINGS, INC. | ||
|
|
|
Dated: September 14, 2007 | By: | /s/ Michael T. Flavin |
| Name: | Michael T. Flavin, Ph.D. |
| Title: | Chairman and Chief Executive Officer |
3